The FDA will put three psychedelic drug programs on an ultra-fast approval track, compressing review timelines from roughly ...

P004 represents a first-in-class application of GLP-1 receptor agonism in the intra-articular space, specifically targeting patients with knee osteoarthritis and synovitis who have failed multiple ...

President Trump issued an executive order to fast-track psychedelic therapies like ibogaine to treat PTSD and other mental ...

Some psychedelic drugs, once considered fringe, are now getting a step closer to possibly being approved for use as mental ...

Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Coramitug is being evaluated by Novo Nordisk in the ongoing Phase 3 ...

The federal government is opening the door for more research on psychedelics—and potential future approval—as a form of ...

Coramitug is designed to clear toxic protein deposits from the heart, offering a new approach to treating ATTR cardiomyopathy ...

President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push to clear ...

The AIM-listed biotech reports 77% progression-free survival at 20 months, well ahead of the standard of care Scancell ...

The agency issued priority vouchers for 3 experimental new drugs using psilocybin and methylone, amid Trump’s ...

Coramitug is currently being investigated in the phase 3 CLEOPATTRA trial in approximately 1280 patients with ATTR-CM.

Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and additi ...